Skip to main content
. 2020 Apr 25;22:100293. doi: 10.1016/j.eclinm.2020.100293

Fig. 2.

Fig 2

Competing cumulative risk of clearance, progression (to CIN3+), and persistence of type-specific [1] HPV infections over 7 years of follow-up.

1Competing cumulative incidences for progression and clearance were calculated as the weighted average of the estimated cumulative incidence rates for each type-specific HPV infection, where weights were based on the subgroup sample size.